(Q35198927)

7 August 2017

1 reference

title

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma (English)

1 reference

7 August 2017

0 references

Wechalekar AD

1

1 reference

7 August 2017

Chen CI

2

1 reference

7 August 2017

Sutton D

3

1 reference

7 August 2017

Reece D

4

1 reference

7 August 2017

Voralia M

5

1 reference

7 August 2017

Stewart AK

6

1 reference

7 August 2017

1 July 2003

1 reference

7 August 2017

1 reference

7 August 2017

44

1 reference

7 August 2017

1147-1149

1 reference

7 August 2017

7

1 reference

Update on the treatment of multiple myeloma

7 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Thalidomide in the treatment of relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000067918

10.1080/1042819031000067918

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference